儿童哮喘急性发作治疗指南推荐分析:PERN研究
该观察性研究分析了来自全球六个区域儿科急诊研究网络的158份儿童急性哮喘管理指南,发现吸入短效β受体激动剂和全身性皮质类固醇的推荐一致,但严重发作的其他治疗推荐不一致,且指南在利益相关者参与、制定严谨性、适用性和编辑独立性等方面质量较低。
要点
- 多数指南推荐吸入短效β受体激动剂和全身性皮质类固醇用于儿童哮喘急性发作。
- 严重和危重哮喘中,吸入抗胆碱能药物推荐较多,但轻中度推荐不一致。
- 指南在利益相关者参与、制定严谨性、适用性和编辑独立性方面评分较低。
核心结论
- 当前儿童急性哮喘发作指南在重要质量领域存在显著缺陷,对严重发作的指导有限且不一致。
研究设计与样本
- 观察性研究,纳入全球六个区域儿科急诊研究网络机构的158份儿童急性哮喘管理指南。
主要发现
- 半数指南提供至少两个年龄组的推荐,多数指南根据哮喘严重程度提供治疗推荐。
- 吸入短效β受体激动剂和全身性皮质类固醇的推荐一致。
- 多数指南推荐严重和危重哮喘使用吸入抗胆碱能药物,但轻中度推荐不一致。
- 氦氧混合气和雾化镁用于严重和危重疾病的推荐不一致。
- 肠外支气管扩张剂和肾上腺素多保留用于严重和危重哮喘,静脉镁最常被推荐;其他肠外支气管扩张剂(尤其是氨茶碱)的使用存在区域差异。
关键数值与推荐
- 指南质量评估显示清晰度、范围和目的评分高,但利益相关者参与、制定严谨性、适用性和编辑独立性评分低。
临床怎么用
- 临床医生应优先使用吸入短效β受体激动剂和全身性皮质类固醇治疗儿童哮喘急性发作。
- 对于严重发作,使用吸入抗胆碱能药物、氦氧混合气、雾化镁、肠外支气管扩张剂等需注意指南推荐不一致。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: There is significant practice variation in acute paediatric asthma, particularly severe exacerbations. It is unknown whether this is due to differences in clinical guidelines. OBJECTIVES: To describe and compare the content and quality of clinical guidelines for the management of acute exacerbations of asthma in children between geographic regions. METHODS: Observational study of guidelines for the management of acute paediatric asthma from institutions across a global collaboration of six regional paediatric emergency research networks. MEASUREMENTS AND MAIN RESULTS: 158 guidelines were identified. Half provided recommendations for at least two age groups, and most guidelines provided treatment recommendations according to asthma severity.There were consistent recommendations for the use of inhaled short-acting beta-agonists and systemic corticosteroids. Inhaled anticholinergic therapy was recommended in most guidelines for severe and critical asthma, but there were inconsistent recommendations for its use in mild and moderate exacerbations. Other inhaled therapies such as helium-oxygen mixture (Heliox) and nebulised magnesium were inconsistently recommended for severe and critical illness.Parenteral bronchodilator therapy and epinephrine were mostly reserved for severe and critical asthma, with intravenous magnesium most recommended. There were regional differences in the use of other parenteral bronchodilators, particularly aminophylline.Guideline quality assessment identified high ratings for clarity of presentation, scope and purpose, but low ratings for stakeholder involvement, rigour of development, applicability and editorial independence. CONCLUSIONS: Current guidelines for the management of acute paediatric asthma exacerbations have substantial deficits in important quality domains and provide limited and inconsistent guidance for severe exacerbations.
引用
- Craig S, Collings M, Gray C, et al. Analysis of guideline recommendations for treatment of asthma exacerbations in children: a Pediatric Emergency Research Networks (PERN) study. Arch Dis Child. 2024. PMID: 38325912. doi:10.1136/archdischild-2023-326739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。